Journals / Harran Üniversitesi Tıp Fakültesi Dergisi / 2021 / Cilt: 18 - Sayı: 2

Evaluation Of The Relationship Between Stomach Cancer and Preoperative Anemia

Mide Kanseri Ve Preoperatif Anemi Arasındaki İlişkinin Değerlendirilmesi

Pages
240–245
Publication Date
2021-08-27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When planning the treatment of patients with gastric cancer, it should not be overlooked that patients with preoperative anemia may have more aggressive tumor characteristics.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: One of the most common preoperative clinical problems of cancer patients is preoperative anemia and one of the most common types of cancer with preoperative anemia is stomach cancer.
📊
Key Findings & Data:Materials and Methods: The clinicopathological and demographic characteristics of patients who underwent curative D2 gastrectomy and R0 resection due to gastric cancer between January 1, 2017 and December 1, 2019 in Cumhuriyet University Department of Surgical Oncology were retrospectively analyzed.
💡
Conclusion & Impact:When planning the treatment of patients with gastric cancer, it should not be overlooked that patients with preoperative anemia may have more aggressive tumor characteristics.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:preoperatif anemi · mide kanseri · hemoglobin

Abstract

Background: One of the most common preoperative clinical problems of cancer patients is preoperative anemia and one of the most common types of cancer with preoperative anemia is stomach cancer. However, the relationship between stomach cancer and anemia is not clear. The aim of this study is to examine the relationship between preoperative anemia and tumor size and tumor stage by comparing the pathological stages and tumor sizes, which are independent prognostic risk factors, with preoperative hemoglobin values, and to investigate the prognostic value of preoperative anemia for gastric cancer with poor prognostic markers. Materials and Methods: The clinicopathological and demographic characteristics of patients who underwent curative D2 gastrectomy and R0 resection due to gastric cancer between January 1, 2017 and December 1, 2019 in Cumhuriyet University Department of Surgical Oncology were retrospectively analyzed. Results : A total of 85 patients were examined. 66 (77.6%) of the patients were male and 19 (22.4%) were female. Total gastrectomy was performed in 55 (64.7%) patients and 30 (35.2%) patients underwent subtotal gastrectomy. All patients were diagnosed with adenocarcinoma. 48 (56.5%) of the patients were stage 3, 29 (34.1%) were stage 2, 8 (9.4%) were stage 1. Tumor size of 51 (60%) patients was large and 34 (40%) patients were small. 51 (60%) patients had anemia. Conclusion : The tumor size of gastric cancer patients with preoperative anemia is larger and their tumors are advanced. When planning the treatment of patients with gastric cancer, it should not be overlooked that patients with preoperative anemia may have more aggressive tumor characteristics.

Özet

Giriş Amaç: Kanser hastalarının preoperatif en sık görülen klinik problemlerinden biri preoperatif anemidir. Preoperatif aneminin en sık görüldüğü kanser türlerinden biri mide kanseridir. Fakat, mide kanserinin anemi ile ilişkisi net değildir. Bu çalışmanın amacı mide kanserli hastaların bağımsız prognostik risk faktör olan patolojik evrelerinin ve tümör boyutlarının ameliyat öncesi hemoglobin değerleriyle karşılaştırarak preoperatif anemi ile tümör boyutu ve tümör evresi arasındaki ilişkiyi incelemek ve prognostik belirteçleri zayıf olan mide kanseri için preoperatif aneminin prognostik değerini araştırmaktır. Materyal ve Metod : XX üniversitesi XX bölümünde 1 ocak 2017 ile 1 aralık 2019 yılları arasında mide kanseri dolayısıyla küratif D2 gastrektomi ve Ro rezeksiyon uygulanmış hastaların klinikopatolojik ve demografik özellikleri retrospektif olarak incelendi. Bulgular : Toplam 85 hasta incelendi. Hastaların 66 (%77,6)’sı erkek 19 (%22,4)’u kadındı. Hastaların yaş ortalaması 68,1(41-87) idi. 55(%64,7) hastaya total gastrektomi 30 (%35,2) hastaya subtotal gastrektomi uygulandı. Hastaların tümü adenokarsinom tanılı idi. Hastaların 48(%56,5)’i evre 3, 29(%34,1)’u evre 2, 8(%9,4)’i evre 1 idi. 51(%60) hastanın tümör boyutu büyük 34(%40) hastanın küçüktü.51(%60) hastanın anemisi vardı. Sonuç : Preoperatif anemisi bulunan mide kanserli hastaların tümör boyutları daha büyük ve ileri evre tümörlerdir. Mide kanserli hastaların tedavisi planlanırken preoperatif anemisi bulunan hastaların tümör özelliklerinin daha agresif olabileceği gözardı edilmememidir.

🔖

Cite This Article

MOLLAOĞLU, M. C., BOSTANCI, M., KARADAYI, K. (2021). Evaluation Of The Relationship Between Stomach Cancer and Preoperative Anemia. Harran Üniversitesi Tıp Fakültesi Dergisi, Cilt: 18 - Sayı: 2, 240–245. https://ajindex.com/articles/406369

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Referans1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019
  2. 69(1):7-34. Referans 2 Das M. Neoadjuvant chemotherapy: survival benefit in gastric cancer. The Lancet Oncology. 2017
  3. 18(6):e307. Referans 3 Lv X, Zhang L, Huang R, Song W. A clinical exploration of neoadjuvant chemotherapy with tegafur, gimeracil, and oteracil potassium capsules combined with oxaliplatin for advanced gastric cancer. International journal of clinical and experimental medicine. 2015
  4. 8(10):19030. Referans 4 Zhang X-y, Zhang P-y. Gastric cancer: somatic genetics as a guide to therapy. Journal of Medical Genetics. 2017
  5. 54(5):305-12. Referans 5 Lordick F, Kang Y-K, Chung H-C, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. The lancet oncology. 2013
  6. 14(6):490-9. Referans 6 Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AFC, Wotherspoon A, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. The lancet oncology. 2013
  7. 14(6):481-9. Referans 7 Blakely AM, Miner TJ. Surgical considerations in the treatment of gastric cancer. Gastroenterology Clinics. 2013
  8. 42(2):337-57. Referans 8 Tan VP, Wong BC. Gastric cancer chemoprevention: the current evidence. Gastroenterology Clinics. 2013
  9. 42(2):299-316. Referans 9 Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO molecular medicine. 2012
  10. 4(3):143-59. Referans 10 Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. The Lancet. 2009
  11. 374(9688):477-90. Referans 11 Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nature Clinical Practice Oncology. 2005
  12. 2(2):98-107. Referans 12 Shiozaki H, Shimodaira Y, Elimova E, Wadhwa R, Sudo K, Harada K, et al. Evolution of gastric surgery techniques and outcomes. Chinese journal of cancer. 2016
  13. 35(1):69. Referans 13 Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology. 2010
  14. 17(6):1471-4. Referans 14 Hosoda K, Yamashita K, Katada N, Moriya H, Mieno H, Sakuramoto S, et al. Preoperative tumor size is a critical prognostic factor for patients with Borrmann